tavaborole

(redirected from Kerydin)

tavaborole

(ta-va-bor-ole),

Kerydin

(trade name)

Classification

Therapeutic: antifungals
Pharmacologic: temporary class
Pregnancy Category: C

Indications

Topical treatment of toenail onychomycosis.

Action

Inhibits fungal protein synthesis via inhibition of aminoacyl-transfer ribonucleic acid (tRNA) synthetase (AARS).

Therapeutic effects

Resolution of toenail fungus.
Active against Trychophyton rubrum and Trychophyton mentagrophytes.

Pharmacokinetics

Absorption: Minimal absorption follows topical administration.
Distribution: Unknown.
Metabolism and Excretion: Extensively metabolized, metabolites are eliminated mostly in urine.
Half-life: Unknown.

Time/action profile (resolution of infection)

ROUTEONSETPEAKDURATION
Topunknownunknown48 wk†
† Length of treatment necessary for resolution of infection.

Contraindications/Precautions

Contraindicated in: None noted.
Use Cautiously in: Geriatric: Elderly may be more sensitive to drug effects; Obstetric: Use during pregnancy only if potential benefit justifies potential risk to fetus; Use cautiously if breastfeeding; Pediatric: Safe and effective use in children has not been established.

Adverse Reactions/Side Effects

Local

  • dermatitis
  • erythema
  • exfoliation
  • ingrown toenail

Interactions

Drug-Drug interaction

None noted.

Route/Dosage

Topical (Adults) Apply to affected nail once daily for 48 wk.

Availability

Topical solution: 5% in 12-mL bottle with enclosed dropper

Nursing implications

Nursing assessment

  • Inspect involved areas of skin and mucous membranes before and frequently during therapy. Increased skin irritation may indicate need to discontinue medication.

Potential Nursing Diagnoses

Risk for impaired skin integrity (Indications)
Risk for infection (Indications)

Implementation

  • Topical: Apply daily for 48 wks to clean, dry toenail surface and under tip of toenail. Avoid contact with skin other than skin immediately surrounding treated nail. Wipe excess solution away from surrounding skin. Allow solution to dry following application. Avoid contact with eyes or mucous membranes.

Patient/Family Teaching

  • Instruct patient to apply medication as directed for full course of therapy, even if feeling better. Emphasize the importance of avoiding the eyes. Caution patient that solution is flammable; avoid use near heat or open flame. Discard bottle 3 mo after inserting dropper. Advise patient to read Patient Information sheet prior to starting therapy and with each Rx refill in case of changes.
  • Advise patient to notify health care professional if area of application shows signs of persistent irritation (redness, itching, swelling, skin peeling, ingrown toenail).
  • Advise patient to notify health care professional of all Rx or OTC medications, vitamins, or herbal products being taken and to consult with health care professional before taking other medications.
  • Advise female patient to notify health care professional if pregnancy is planned or suspected or if breastfeeding.

Evaluation/Desired Outcomes

  • Resolution of toenail fungus.
References in periodicals archive ?
Also during this period, Anacor received FDA approval for Kerydin (tavaborole), a novel, boron-based topical treatment for onychomycosis, entered into a commercialisation partnership with Novartis for Kerydin, and successfully completed Phase 3 development for Eucrisa (crisaborole), a novel, boron-based topical treatment for atopic dermatitis.
Anacor also holds the rights to Kerydin, a topical treatment for onychomycosis (toenail fungus) that is commercialized by Sandoz Inc.
Apart from crisaborole and Kerydin, Anacor has discovered three investigational compounds that have been out-licensed for additional development.
M2 EQUITYBITES-September 23, 2014-Anacor Pharmaceuticals unveils antifungal drug KERYDIN (tavaborole) Topical Solution, 5% in the US
KERYDIN is the first oxaborole antifungal indicated for the topical treatment of onychomycosis of the toenails, a fungal infection of the nail and nail bed.
We await action by the FDA this summer on our Kerydin NDA and look forward to launching pivotal studies of AN2728 in mild-to-moderate atopic dermatitis patients.
M2 PHARMA-September 23, 2014-Anacor Pharmaceuticals unveils antifungal drug KERYDIN (tavaborole) Topical Solution, 5% in the US
M2 EQUITYBITES-July 22, 2014-Anacor Pharmaceuticals partners with Sandoz for commercialisation of KERYDIN in the US
Biopharmaceutical company Anacor Pharmaceuticals (NasdaqGM:ANAC) revealed on Monday the launch of an agreement to distribute and commercialise its drug KERYDIN (tavaborole) topical solution, 5% in the US through Sandoz, a Novartis company.
PharmaDerm, the branded dermatology business of Sandoz, will be responsible for the sales and marketing of KERYDIN, the US Food and Drug Administration (FDA) approved antifungal drug approved for the topical treatment of onychomycosis of the toenails, a fungal infection of the nail and nail bed.
Under the agreement, Anacor will supply KERYDIN to Sandoz through Anacor's contract manufacturers; Sandoz will be responsible for all of its selling, marketing, distribution, general and administrative costs related to the commercialisation of KERYDIN; Anacor will hold the NDA and is responsible for any further development.
M2 PHARMA-July 22, 2014-Anacor Pharmaceuticals partners with Sandoz for commercialisation of KERYDIN in the US